Peer-reviewed veterinary case report
Oral remdesivir treatment outcomes in 29 cats with feline infectious
By Kelsey Ann Renner et al.·Published in Journal of Feline Medicine and Surgery·2025·Animal Referral Centre, Auckland, New Zealand, GB·View original on DOAJ →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy of oral remdesivir in treating feline infectious peritonitis: a prospective observational study of 29 cats
- Species:
- cat
Plain-English summary
A group of 29 cats diagnosed with feline infectious peritonitis (FIP) were treated with oral remdesivir to see how well it worked. Most of the cats, 25 out of 29, went into remission and survived for more than six months, with many achieving this within about 12 weeks. Some cats needed additional treatment with molnupiravir if they relapsed. The study found that while oral remdesivir was effective, cats with non-effusive FIP had a higher chance of relapse compared to those with the effusive form of the disease.
People also search for: cat FIP treatment · feline infectious peritonitis remission · oral remdesivir for cats
Abstract
Objectives The primary aim of this prospective observational study was to document clinical progression, survival, remission and relapse in New Zealand cats with feline infectious peritonitis (FIP) that were treated with compounded oral remdesivir with or without initial parenteral remdesivir therapy. The secondary aims were to determine the optimal monitoring protocols and report the adverse effects of treatment and complications associated with FIP. Methods A total of 29 client-owned cats with a clinical diagnosis of FIP were prospectively recruited. Cats were administered oral remdesivir (30 mg/kg q24h), rounded up to the nearest capsule size as the sole treatment, or after initial parenteral remdesivir (15–30 mg/kg q24h). Rechecks were recommended at weeks 1, 2, 4, 8 and 12 during treatment, and at 2 and 12 weeks after treatment. A full physical examination (including neurological and ophthalmic examination) and point-of-care ultrasound were performed at each recheck. A complete blood count and biochemistry panel were performed at weeks 4, 8, 12 and 24. Molnupiravir was offered as a rescue therapy for cats that relapsed. Results In total, 25 (86%) cats entered remission and survived beyond 6 months (range 6–27). A total of 22 (75%) cats achieved remission within 84 days while receiving oral remdesivir. Three cats received subsequent molnupiravir rescue therapy to achieve remission. Five cats (20%) experienced relapse: four with non-effusive disease and one with effusive disease. Notably, 4/8 (50%) non-effusive cases relapsed, compared with only 1/20 (5%) with effusive disease. Conclusions and relevance This study demonstrates that oral remdesivir at a dose rate of 30 mg/kg q24h is an effective treatment for effusive FIP. The survival rate in non-effusive cats was significantly lower; therefore, an increased dose rate or frequency of administration should be considered in these cats. Oral remdesivir is a viable antiviral option where GS-441524 is unavailable.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on DOAJ: https://doi.org/10.1177/1098612X251335189